Six Research Updates

Today, we delve into the complicated world of psychiatric diagnoses and their impact on treatment.CME: Take the CME Post-Test for this EpisodePublished On: 11/11/2024Duration: 34 minutes, 20 secondsMark L. Ruffalo, MSW, DPsa and Nassir Ghaemi, MD, MPH, have disclosed no relevant financial or other interests in any commercial companies pertaining to this educational activity.

How to assess med response when the patient reports is a poor guide: long-term mood stabilizers, sleep meds, and rapid cycling.CME: Take the CME Post-Test for this EpisodePublished On: 11/04/2024Duration: 18 minutes, 12 secondsChris Aiken and Kellie Newsome, PMHNP have disclosed no relevant financial or other interests in any commercial companies pertaining to this educational activity.

A new med combo for alcohol use disorder, antipsychotic dose reduction in schizophrenia, and two new tips for using stimulants in ADHD.CME: Take the CME Post-Test for this EpisodePublished On: 10/28/2024Duration: 24 minutes, 12 secondsChris Aiken and Kellie Newsome, PMHNP have disclosed no relevant financial or other interests in any commercial companies pertaining to this educational activity.

New studies change how we think about lithium and weight gain, and updates on lumateperone, lavender, and esketamine in depressionCME: Take the CME Post-Test for this EpisodePublished On: 10/21/2024Duration: 24 minutes, 43 secondsChris Aiken and Kellie Newsome, PMHNP have disclosed no relevant financial or other interests in any commercial companies pertaining to this educational activity.

We count down the top 10 research updates of the past year with a focus on treatment resistant depression and benzo withdrawal.CME: Take the CME Post-Test for this EpisodePublished On: 10/14/2024Duration: 19 minutes, 35 secondsChris Aiken and Kellie Newsome, PMHNP have disclosed no relevant financial or other interests in any commercial companies pertaining to this educational activity.

KarXT (Cobenfy) is the first antipsychotic that doesn’t block dopamine. We trace the origins of this new drug to a South Asian herb used for over 5,000 years, up to the three EMERGENT trials that led to its FDA approval.CME: Take the CME Post-Test for this EpisodePublished On: 10/07/2024Duration: 12 minutes, 28 secondsChris Aiken and Kellie Newsome, PMHNP have disclosed no relevant financial or other interests in any commercial companies pertaining to this educational activity.

Today, we are talking about using cognitive behavioral therapy to treat Obsessive-Compulsive Disorder in clinical settings.CME: Take the CME Post-Test for this EpisodePublished On: 09/30/2024Duration: 20 minutes, 20 secondsJoshua Feder, MD, and Mara Goverman, LCSW, have disclosed no relevant financial or other interests in any commercial companies pertaining to this educational activity.

A new medication is knocking on the door for FDA approval in PTSD, and it isn’t MDMA. We cover that, and 8 other off label medications.CME: Take the CME Post-Test for this EpisodePublished On: 09/23/2024Duration: 27 minutes, 18 secondsChris Aiken and Kellie Newsome, PMHNP have disclosed no relevant financial or other interests in any commercial companies pertaining to this educational activity.

Should we follow the FDA and give SSRIs, or venture off label with the fabled prazosin?CME: Take the CME Post-Test for this EpisodePublished On: 09/16/2024Duration: 18 minutes, 35 secondsChris Aiken and Kellie Newsome, PMHNP have disclosed no relevant financial or other interests in any commercial companies pertaining to this educational activity.

Learn what therapies work for PTSD, what goes on in session, and how to prevent PTSD when your patient calls after a trauma.CME: Take the CME Post-Test for this EpisodePublished On: 09/09/2024Duration: 16 minutes, 10 secondsChris Aiken and Kellie Newsome, PMHNP have disclosed no relevant financial or other interests in any commercial companies pertaining to this educational activity.